Nov 2026· Netherlands Heart Journal· Vol 34, pp. 424 - 435· 0 citations· 49 references
Medicine
TL;DR
This review provides a comprehensive overview of the diagnostic pathway, including (AI-enabled) electrocardiography analysis, (non-)invasive imaging modalities, biomarkers, and genetic testing, and emerging therapeutic strategies are discussed.
Abstract
Amyloidosis comprises a group of systemic disorders caused by extracellular deposition of misfolded precursor proteins, leading to progressive organ dysfunction. Cardiac amyloidosis, particularly transthyretin-related amyloid cardiomyopathy (ATTR-CM) has transitioned from a rare and underdiagnosed condition to a treatable disease, driven by major advances in diagnostic imaging, increased disease awareness, and the approval of disease-modifying therapies. These therapies target transthyretin (TTR) stabilization and amyloid production or deposition and have led to an evolving therapeutic landscape. As therapeutic efficacy is greatest in earlier disease stages, timely recognition is crucial. Effective management of ATTR-CM requires structured screening of high-risk populations, multidisciplinary collaboration, and longitudinal follow-up. This review provides a practical, clinician-focused framework that addresses clinical presentation and “red flags” to facilitate early detection. It offers a comprehensive overview of the diagnostic pathway, including (AI-enabled) electrocardiography analysis, (non-)invasive imaging modalities, biomarkers, and genetic testing. Additionally, emerging therapeutic strategies are discussed, encompassing supportive heart failure management, amyloid-specific treatments such as TTR stabilizers and gene silencers, and novel approaches including fibril depletion and gene-editing therapies. As the therapeutic paradigm shifts from disease stabilization toward potential reversal, early diagnosis and personalized treatment strategies are essential to improve prognosis and quality of life in patients with cardiac amyloidosis.
Cardiac amyloidosis is an infiltrative cardiomyopathy caused by extracellular deposition of amyloid fibrils in the myocardium, leading to progressive restrictive dysfunction. The main clinical challenge is delayed diagnosis and differentiation between transthyretin amyloidosis and immunoglobulin light-chain amyloidosis...
K. A. Loginova, Elizaveta S. Aldankova, M. V. Petrov et al.· University proceedings Volga...· 0 citations
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive infiltrative cardiomyopathy increasingly recognised as a cause of heart failure. Advances in the understanding of its pathophysiology have enabled the development of targeted therapies, making ATTR-CM a paradigm of precision medicine in cardiology. Current...
M. T. Basurte-Elorz, G. Lacuey-Lecumberri, N. Mora-Ayestarán· European Cardiology· 0 citations
Variations in ATTR-CM care across Europe highlight key areas for improvement and reveal where interventions could have the greatest impact, as differences in the number of specialized centers, variability in time to treatment initiation, and unequal access to therapies contribute to these disparities.
L. Kieviet, L. Rekker, D. Breucker et al.· European Heart Journal· 0 citations
Cardiac amyloidosis is an increasingly recognized cause of heart failure in the setting of progressive restrictive cardiomyopathy, particularly among older adults, males, and individuals of African descent, with remarkable advances in the therapeutic landscape, but substantial knowledge gaps persist.
Sareen Bains, Harry Atwal, Ashbir Sidhu et al.· Pharmaceuticals· 0 citations
INTRODUCTION
Immunoglobulin light-chain (AL) amyloidosis is associated with high early mortality, particularly when the diagnosis occurs after advanced cardiac or multiorgan dysfunction has developed. Existing reviews have addressed diagnosis and management, but the evolving concept of high-risk disease in the modern t...
Mahmoud Massalha, Tamer Hellou, M. Gertz· Expert Review of Hematology· 0 citations
A narrative review provides a structured overview of the mechanisms, epidemiology, and clinical management of arrhythmias in ATTR-CM, with a focus on clinically relevant decision-making and the potential influence of contemporary DMTs.
I. Ntalas, P. Korantzopoulos, C. Goudis et al.· Journal of Cardiovascular Me...· 1 citation
Related blog posts
MIT News · Artificial Intelligence· news.mit.eduNov 18, 2026
What's new in research at Microsoft? Host Anson Ho explores the latest, including AI-powered universal translation, a breakthrough in a 31-year-old mathematics challenge, and advances making AI coding agents faster and more efficient. The post Microsoft Research Focus – Edition #98 appeared first on Microsoft Research.
MIT News · Artificial Intelligence· news.mit.eduNov 12, 2026
MIT scientists developed a training method to generate models that simulate the effects of human activities on climate much more quickly than other approaches.
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.